Plasma neuron-derived exosomes also contain the AD biomarkers Aβ42 (elevated) and Tau (elevated), whose levels were found to be altered from as much as 10 years before the clinical onset allowing to distinguish between MCI and AD patients [189,190,191]. This evidence concerns the gene MAPT and Alzheimer disease.